Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B.
Daffis S, Balsitis S, Chamberlain J, Zheng J, Santos R, Rowe W, Ramakrishnan D, Pattabiraman D, Spurlock S, Chu R, Kang D, Mish M, Ramirez R, Li L, Li B, Ma S, Hung M, Voitenleitner C, Yon C, Suresh M, Menne S, Cote P, Delaney WE 4th, Mackman R, Fletcher SP. Daffis S, et al. Among authors: pattabiraman d. Hepatology. 2021 Jan;73(1):53-67. doi: 10.1002/hep.31255. Epub 2020 Nov 27. Hepatology. 2021. PMID: 32246499 Free PMC article.
Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators.
Amin OE, Colbeck EJ, Daffis S, Khan S, Ramakrishnan D, Pattabiraman D, Chu R, Micolochick Steuer H, Lehar S, Peiser L, Palazzo A, Frey C, Davies J, Javanbakht H, Rosenberg WMC, Fletcher SP, Maini MK, Pallett LJ. Amin OE, et al. Among authors: pattabiraman d. Hepatology. 2021 Jul;74(1):55-71. doi: 10.1002/hep.31695. Epub 2021 Jun 20. Hepatology. 2021. PMID: 33368377 Free PMC article. Clinical Trial.
Pharmacological induction of chromatin remodeling drives chemosensitization in triple-negative breast cancer.
Bagheri M, Mohamed GA, Mohamed Saleem MA, Ognjenovic NB, Lu H, Kolling FW, Wilkins OM, Das S, LaCroix IS, Nagaraj SH, Muller KE, Gerber SA, Miller TW, Pattabiraman DR. Bagheri M, et al. Among authors: pattabiraman dr. Cell Rep Med. 2024 Apr 16;5(4):101504. doi: 10.1016/j.xcrm.2024.101504. Epub 2024 Apr 8. Cell Rep Med. 2024. PMID: 38593809 Free PMC article.
Alteration of DNMT1/DNMT3A by eribulin elicits global DNA methylation changes with potential therapeutic implications for triple-negative breast cancer.
Bagheri M, Lee MK, Muller KE, Miller TW, Pattabiraman DR, Christensen BC. Bagheri M, et al. Among authors: pattabiraman dr. bioRxiv [Preprint]. 2023 Jun 10:2023.06.09.544426. doi: 10.1101/2023.06.09.544426. bioRxiv. 2023. Update in: Epigenomics. 2024 Mar;16(5):293-308. doi: 10.2217/epi-2023-0339 PMID: 37333096 Free PMC article. Updated. Preprint.
Pharmacological Induction of mesenchymal-epithelial transition chemosensitizes breast cancer cells and prevents metastatic progression.
Bagheri M, Aisha Mohamed G, Mohamed Saleem MA, Ognjenovic NB, Lu H, Kolling FW, Wilkins OM, Das S, La Croix IS, Nagaraj SH, Muller KE, Gerber SA, Miller TW, Pattabiraman DR. Bagheri M, et al. Among authors: pattabiraman dr. bioRxiv [Preprint]. 2023 Apr 21:2023.04.19.537586. doi: 10.1101/2023.04.19.537586. bioRxiv. 2023. PMID: 37131809 Free PMC article. Preprint.
32 results